Spinal Modulation (Menlo Park, California) has enrolled the first patient in its U.S. pivotal trial to evaluate the safety and efficacy of the Axium Neurostimulator System for the treatment of chronic lower limb pain. The company said it announced the first enrollment in the ACCURATE study and presented data about the European experience with the Axium System last week at the 20th annual Napa Pain Conference in Napa, California.